<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01809704</url>
  </required_header>
  <id_info>
    <org_study_id>DC-03267</org_study_id>
    <nct_id>NCT01809704</nct_id>
  </id_info>
  <brief_title>Clinical Validation of New OCT System</brief_title>
  <official_title>Topcon DRI OCT-1 Optical Coherence Tomography System for the Acquisition of Retinal Thickness Measurements and Ocular Images of the Posterior Chamber: Agreement and Precision Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Topcon Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Topcon Medical Systems, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate clinical substantial equivalence of DRI OCT-1 as comparable to the&#xD;
      commercially available Cirrus&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retinal Thickness</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Normal and Ocular Pathology.</condition>
  <arm_group>
    <arm_group_label>Normal</arm_group_label>
    <description>Normal results from clinical exam and free of ocular pathology.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glaucoma</arm_group_label>
    <description>Clinical exam results consistent with glaucoma and visual field defects consistent with glaucoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retina</arm_group_label>
    <description>Clinical exam results consistent with retina pathology</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects that are Normal, or shows signs of Glaucoma or Retinal Ocular Pathology.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Normal Group&#xD;
&#xD;
          1. Subjects 18 years of age or older on the date of informed consent&#xD;
&#xD;
          2. Subjects able to understand the written informed consent and willing to participate as&#xD;
             evidenced by signing the informed consent&#xD;
&#xD;
          3. Subjects presenting at the site with normal eyes (eyes without pathology)&#xD;
&#xD;
          4. IOP â‰¤ 21 mmHg bilaterally&#xD;
&#xD;
          5. BCVA 20/40 or better bilaterally&#xD;
&#xD;
          6. Both eyes must be free of eye disease&#xD;
&#xD;
        Exclusion Criteria for Normal Group&#xD;
&#xD;
          1. Subjects unable to tolerate ophthalmic imaging&#xD;
&#xD;
          2. Subject with ocular media not sufficiently clear to obtain acceptable OCT images&#xD;
&#xD;
          3. HFA visual field (24-2 Sita Standard, white on white) result abnormal, defined as GHT&#xD;
             'Outside Normal Limits' and/or PSD &lt; 1%&#xD;
&#xD;
          4. HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on&#xD;
             manufacturer's recommendation), defined as fixation losses &gt; 33% or false positives &gt;&#xD;
             25%, or false negatives &gt; 25%&#xD;
&#xD;
          5. Presence of any ocular pathology except for cataract&#xD;
&#xD;
          6. Previous ocular surgery or laser treatment other than uncomplicated refractive&#xD;
             procedure or cataract surgery performed within six months prior to study scanning&#xD;
&#xD;
          7. Narrow angle&#xD;
&#xD;
          8. History of leukemia, dementia or multiple sclerosis&#xD;
&#xD;
          9. Concomitant use of hydroxychloroquine and chloroquine&#xD;
&#xD;
        Inclusion Criteria for Glaucoma Group&#xD;
&#xD;
          1. Subjects 18 years of age or older on the date of informed consent&#xD;
&#xD;
          2. Subjects able to understand the written informed consent and willing to participate as&#xD;
             evidenced by signing the informed consent&#xD;
&#xD;
          3. Subjects presenting at the site with glaucoma&#xD;
&#xD;
          4. BCVA 20/40 or better in the study eye&#xD;
&#xD;
          5. HFA visual field (24-2 Sita Standard, white on white) result abnormal, defined as GHT&#xD;
             'Outside Normal Limits' and/or PSD &lt; 1% in the study eye&#xD;
&#xD;
        Exclusion Criteria for Glaucoma Group&#xD;
&#xD;
          1. Subjects unable to tolerate ophthalmic imaging&#xD;
&#xD;
          2. Subject with ocular media not sufficiently clear to obtain acceptable OCT images&#xD;
&#xD;
          3. HFA visual field (24-2 Sita Standard, white on white) result unreliable, defined as&#xD;
             fixation losses &gt; 33% or false positives &gt; 25%, or false negatives &gt; 25% in the study&#xD;
             eye&#xD;
&#xD;
          4. Presence of any ocular pathology except glaucoma in the study eye&#xD;
&#xD;
          5. Previous ocular surgery or laser treatment other than uncomplicated procedures&#xD;
             performed within six months prior to study scanning in the study eye&#xD;
&#xD;
          6. History of leukemia, dementia or multiple sclerosis&#xD;
&#xD;
          7. Concomitant use of hydroxychloroquine and chloroquine&#xD;
&#xD;
        Inclusion Criteria for Retina Disease Group&#xD;
&#xD;
          1. Subjects 18 years of age or older on the date of informed consent&#xD;
&#xD;
          2. Subjects able to understand the written informed consent and willing to participate as&#xD;
             evidenced by signing the informed consent&#xD;
&#xD;
          3. Subjects presenting at the site with retinal disease&#xD;
&#xD;
          4. IOP &lt;= 21 mmHg in the study eye&#xD;
&#xD;
          5. BCVA 20/400 or better in the study eye&#xD;
&#xD;
          6. Diagnosis of some type of retinal pathology by investigator, may include, but not&#xD;
             limited to: Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy,&#xD;
             Macular Hole, Epiretinal Membrane, Cystoid Macula Edema, and others&#xD;
&#xD;
        Exclusion Criteria for Retinal Disease Group&#xD;
&#xD;
          1. Subjects unable to tolerate ophthalmic imaging&#xD;
&#xD;
          2. Subject with ocular media not sufficiently clear to obtain acceptable OCT images&#xD;
&#xD;
          3. Presence of glaucoma or any ocular pathology other than a Retinal pathology (e.g.,&#xD;
             cornea pathology) in the study eye&#xD;
&#xD;
          4. Previous ocular surgery or laser treatment other than uncomplicated procedures&#xD;
             performed within six months prior to study scanning in the study eye&#xD;
&#xD;
          5. Narrow angle in the study eye&#xD;
&#xD;
          6. History of leukemia, dementia or multiple sclerosis&#xD;
&#xD;
          7. Concomitant use of hydroxychloroquine and chloroquine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Sinai, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of Clinical Marketing</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamilton Glaucoma Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Murray Fingeret</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitreous Retina Macula Consultants of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>March 8, 2013</study_first_submitted>
  <study_first_submitted_qc>March 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2013</study_first_posted>
  <last_update_submitted>January 22, 2014</last_update_submitted>
  <last_update_submitted_qc>January 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

